Preprint
Brief Report
Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients
This version is not peer-reviewed.
Submitted:
19 March 2020
Posted:
23 March 2020
Read the latest preprint version here
A peer-reviewed article of this preprint also exists.
Abstract
The article describes the rational for inhibition of the angiotensin-converting enzyme 2 (ACE2) pathways as specific targets in patients infected by SARS-CoV-2.
Keywords:
Severe Acute Respiratory Syndrome Coronavirus-2
; (soluble) ACE2
; eosinophil
; asthma
; IL-10
; IL-6
; Lung fibrosis
; Ang (1-7)
; hypoxia
; infarction
; hypertension
Preprints on COVID-19 and SARS-CoV-2
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Downloads
1958
Views
1302
Comments
0
Subscription
Notify me about updates to this article or when a peer-reviewed version is published.
MDPI Initiatives
Important Links
© 2025 MDPI (Basel, Switzerland) unless otherwise stated